语言版本

Time of issue:2021-09-02 16:56:33

中文 English





搜索

Search





01





01





30 Year

API Production & CDMO

700 m³

Reaction Volume

50+

Approval of drug administration agency

100+

R & D Products

01





COMPANY PROFILE

Chongqing Huapont Shengchem Pharm Co., Ltd, founded in 1994, is the wholly owned subsidiary of Chongqing Huapont Pharm Co.，Ltd, a member of Huapont Life Science Co., Ltd. which is a non-state owned public company listed in Shenzhen Stock Exchange (#002004). The company provide integrated services of R&D, production, CDMO and sale of intermediates and APIs for domestic and overseas market.

More >>

PRODUCTS

Fulvestrant

CAS：129453-61-8

FASLODEX is indicated for the treatment of hormone receptor positive metastatic breast cancer in postmenopausal women with disease progression following antiestrogen therapy.

Number of views:

1000

Keywords:

treatment

disease

indicated

metastatic

in

for

progression

is

faslodex

Nintedanib esylate

CAS：656247-18-6

Nintedanib esylate is a small molecule tyrosine kinase inhibitor with antifibrotic and anti-inflammatory activities for the treatment of idiopathic pulmonary fibrosis.

Number of views:

1000

Keywords:

small

treatment

for

pulmonary

is

the

with

fibrosis.

kinase

Ruxolitinib phosphate

CAS：1092939-17-7

US-DMF

Ruxolitinib phosphate is indicated for the treatment of patients with intermediate or high-risk myelofibrosis, including primary myelofibrosis (PMF) (also known as chronic idiopathic myelofibrosis), post-polycythemia vera myelofibrosis (PPV-MF), orpost-essential thrombocythemia myelofibrosis (PET-MF).

Number of views:

1000

Keywords:

myelofibrosis

known

More >>

CMO/CDMO

The company has highly graduated researchers, famous-brand equipment, scientific quality management system and extensive production experience. The company provide all stage CMO/CDMO services for process R&D, and scale-up, validation and commercial production.

More >>